Clinical Results

Clinical Evidence. Real-World Data. Applied Science.

Our Research Programme

Understanding healthy ageing through multiple evidence streams. Healthy ageing is complex and cannot be adequately assessed through a single measurement.

For that reason, our research programme combines evidence from a randomised controlled clinical trial, advanced biological age assessment, real world biometric monitoring, and photobiology research.

At the centre of the programme is a 12 week, randomised, double blind, placebo controlled clinical trial evaluating outcomes across cognition, sleep, libido, skin health, and hair health. Biological ageing is assessed within the same study using multiple DNA epigenetic methylation clocks together with GlycanAge analysis, providing insight into biological age and inflammaging.

Alongside the clinical trial, The Circle provides real world physiological and behavioural data through continuous wearable monitoring and participant reported outcomes, allowing us to understand how changes observed in research settings translate into everyday life.

The programme also includes an ongoing photobiology study investigating the effect of oral nutritional intervention on Minimal Erythema Dose (MED), a recognised measure of skin sensitivity to ultraviolet radiation.

Together, these complementary evidence streams provide a broader understanding of healthspan than any single study, biomarker, or endpoint alone.

01 Randomised Controlled Clinical Trial

Comprehensive Clinical Evaluation

A 12 week, randomised, double blind, placebo controlled clinical trial designed to evaluate the effects of Advanced ID across multiple domains of healthspan.

Clinical outcomes assessed include cognition, sleep, libido, skin hydration, skin barrier function, wrinkle appearance, hair health, and biological ageing.

Biological Age Assessment

Biological age is being assessed using multiple DNA epigenetic methylation clocks together with GlycanAge analysis, a validated measure of age related glycosylation patterns and inflammaging.

The DNA methylation panel includes HRS InCHPhenoAge, Robust PhenoAge, Robust Horvath, Robust Hannum, GrimAge2 variants, Dunedin Pace of Ageing measures, and DNA methylation derived telomere length, providing a comprehensive assessment of biological ageing across multiple validated frameworks.

Results from the randomised controlled trial are currently being analysed.

Preliminary Biological Age Findings

Prior to completion of the randomised controlled trial, biological age testing was performed in a pilot cohort from The Circle.

Across multiple independent DNA methylation clocks, participants demonstrated improvements in biological age measures, including statistically significant reductions of 5.2 years in HRS InCHPhenoAge, 4.1 years in Robust PhenoAge, 3.0 years in Robust Horvath, and 2.4 years in GrimAge2 Tuned. Improvements were also observed in measures of ageing pace, suggesting changes were not limited to biological age estimates alone.

These preliminary findings informed the expansion of biological age assessment within our randomised controlled trial. Full placebo controlled biological age results, including DNA methylation clock analysis and GlycanAge inflammaging data, remain pending.

02 The Circle

Real World Healthspan Monitoring

The Circle Results

01 Continuous Biometric Tracking

Continuous WHOOP monitoring provided objective physiological insight throughout the 12-week programme, complementing participant-reported outcomes.

02 Participant Reported Outcomes

Structured questionnaires completed at Baseline, Week 4, Week 8 and Week 12 assessed Energy, Sleep, Recovery, Cognitive Function, and Skin, Hair & Nail Health. An overall ID Score combined these health markers into a single measure of participant progress.

Sleep & Recovery

Energy

Cognitive Function

Skin, Hair & Nail Health

Sexual Wellbeing

67% experienced an improvement in healthy sex drive

03 Photobiology Study

Assessing Oral Photoprotection

Results pending

The Future of Longevity Is Measurable

For decades, health interventions have relied largely on subjective outcomes and long term disease endpoints.

Advances in biological age testing, wearable technology, and clinical measurement now allow us to evaluate healthspan with far greater precision.

By combining clinical research, biological age assessment, and continuous biometric monitoring, Advanced ID represents a data driven approach to understanding how individuals age, recover, perform, and function over time.